Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)

Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y) Publisher Pubmed

Izadi S^{1, 2} ; Moslehi A¹ ; Kheiry H³ ; Kiani FK¹ ; Ahmadi A⁴ ; Masjedi A⁵ ; Ghani S⁶ ; Rafiee B⁷ ; Karpisheh V¹ ; Hajizadeh F¹ ; Atyabi F⁸ ; Assali A⁸ ; Tekie FSM⁹ ; Namdar A¹⁰ Show All Authors

Izadi S^{1, 2}
Moslehi A¹
Kheiry H³
Kiani FK¹
Ahmadi A⁴
Masjedi A⁵
Ghani S⁶
Rafiee B⁷
Karpisheh V¹
Hajizadeh F¹
Atyabi F⁸
Assali A⁸
Tekie FSM⁹
Namdar A¹⁰
Ghalamfarsa G¹¹
Sojoodi M¹²
Jadidiniaragh F^{1, 13}

Source: Pharmaceutical Research Published:2022

Abstract

The Editor-in-Chief has retracted this article because of similarities between figures within this article, as well as between figures in this article and previously published work [1]. In particular: • Figure 4C (panel CT-26 GAPDH) has similarities with Figure 4C (panel 4T1 GAPDH). • Figure 6a (panel untreated vs 4T1) has similarities with Figure 6a (panel NP. Vs 4T1) of [1]. • Figure 6a (panel Untreated vs B16-F10) has similarities with Figure 6a (panel NP. Vs B16-F10) of [1]. • Figure 6a (panel NP-siRNA HIF-1α vs CT26) has similarities with Figure 6a (panel NP-siRNA CD73 vs CT26) of [1]. • Figure 6a (panel NP-siRNA HIF-1α – Dinaciclib vs 4T1) has similarities with Figure 6a (panel NP-siRNA CD73/ HIF-1α vs CT26) of [1]. • Figure 7a (panel Untreated vs 4T1) has similarities with Figure 7a (panel NP-siRNA HIF-1α vs 4T1) of [1]. • Figure 7a (panel Untreated vs B16-F10) has similarities with Figure 7a (panel Untreated vs 4T1) of [1]. • Figure 7a (panel Untreated vs CT26) has similarities with Figure 7a (panel NP-siRNA HIF-1α vs B16F10) of [1]. The authors Farhad Jadidi-Niaragh, Sepideh Ghani, Afshin Namdar, Farnaz Hajizadeh, Ghasem Ghalamfarsa, Vahid Karpisheh, Mozhdeh Sojoodi and Armin Ahmadi agree to this retraction. The authors Sepideh Izadi, Farnaz Sadat Mirzazadeh Tekie and Akram Assali do not agree to this retraction. The authors Ali Masjedi and Asma Moslehi have not explicitly stated whether they agree or disagree with this retraction. The authors Fariba Karoon Kiani, Behnam Rafiee and Fatemeh Atyabi have not responded to any correspondence from the editor about this retraction. The editor was not able to obtain a current email address for author Hadiseh Kheyri. 1. Hajizadeh F, Ardebili SM, Moornani MB, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, Azizi G. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. European journal of pharmacology. 2020 Sep 5;882:173,235. © Springer Science+Business Media, LLC, part of Springer Nature 2022.

Related Docs

View other Related Docs

1. Retraction To: Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and Ca1 Regions of Hippocampus Via Creb/Bdnf Pathway in Rats (Neurotoxicity Research, (2017), 31, 3, (373-399), 10.1007/S12640-016-9695-4), Neurotoxicity Research (2024)

2. Retraction Notice to “Silencing of Il-6 and Stat3 by Sirna Loaded Hyaluronate-N,N,N-Trimethyl Chitosan Nanoparticles Potently Reduces Cancer Cell Progression” [Int. J. Biol. Macromol. 149 (2020) 487–500, (S0141813019378031), (10.1016/J.Ijbiomac.2020.01.273)], International Journal of Biological Macromolecules (2025)

3. Retraction Notice to “Evaluation of the Treatment Strategies on Patient-Derived Xenograft Mice of Human Breast Tumor” [Eur. J. Pharmacol. 889 (2020) 173605] (European Journal of Pharmacology (2020) 889, (S001429992030697x), (10.1016/J.Ejphar.2020.173605)), European Journal of Pharmacology (2024)

Experts (# of related papers)

View all Related Experts

Alimohammad Alizadeh (3)

Mohammad Abdollahi (2)

Style	Citing Format
MLA	Izadi S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research, vol. 39, no. 12, 2022, pp. 3383-3384.
APA	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, Rafiee B, Karpisheh V, Hajizadeh F, Atyabi F, Assali A, Tekie FSM, Namdar A, Ghalamfarsa G, Sojoodi M, Jadidiniaragh F (2022). Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research, 39(12), 3383-3384.
Chicago	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research 39, no. 12 (2022): 3383-3384.
Harvard	Izadi S et al. (2022) 'Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)', Pharmaceutical Research, 39(12), pp. 3383-3384.
Vancouver	Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, et al.. Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research. 2022;39(12):3383-3384.
BibTex	@article{ author = {Izadi S and Moslehi A and Kheiry H and Kiani FK and Ahmadi A and Masjedi A and Ghani S and Rafiee B and Karpisheh V and Hajizadeh F and Atyabi F and Assali A and Tekie FSM and Namdar A and Ghalamfarsa G and Sojoodi M and Jadidiniaragh F}, title = {Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)}, journal = {Pharmaceutical Research}, volume = {39}, number = {12}, pages = {3383-3384}, year = {2022} }
RIS	TY - JOUR AU - Izadi S AU - Moslehi A AU - Kheiry H AU - Kiani FK AU - Ahmadi A AU - Masjedi A AU - Ghani S AU - Rafiee B AU - Karpisheh V AU - Hajizadeh F AU - Atyabi F AU - Assali A AU - Tekie FSM AU - Namdar A AU - Ghalamfarsa G AU - Sojoodi M AU - Jadidiniaragh F TI - Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y) JO - Pharmaceutical Research VL - 39 IS - 12 SP - 3383 EP - 3384 PY - 2022 ER -

Style

Citing Format

MLA

Izadi S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research, vol. 39, no. 12, 2022, pp. 3383-3384.

APA

Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, Rafiee B, Karpisheh V, Hajizadeh F, Atyabi F, Assali A, Tekie FSM, Namdar A, Ghalamfarsa G, Sojoodi M, Jadidiniaragh F (2022). Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research, 39(12), 3383-3384.

Chicago

Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, Ghani S, et al.. "Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)." Pharmaceutical Research 39, no. 12 (2022): 3383-3384.

Harvard

Izadi S et al. (2022) 'Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)', Pharmaceutical Research, 39(12), pp. 3383-3384.

Vancouver

Izadi S, Moslehi A, Kheiry H, Kiani FK, Ahmadi A, Masjedi A, et al.. Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y). Pharmaceutical Research. 2022;39(12):3383-3384.

BibTex

@article{ author = {Izadi S and Moslehi A and Kheiry H and Kiani FK and Ahmadi A and Masjedi A and Ghani S and Rafiee B and Karpisheh V and Hajizadeh F and Atyabi F and Assali A and Tekie FSM and Namdar A and Ghalamfarsa G and Sojoodi M and Jadidiniaragh F}, title = {Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)}, journal = {Pharmaceutical Research}, volume = {39}, number = {12}, pages = {3383-3384}, year = {2022} }

RIS

TY - JOUR
AU - Izadi S
AU - Moslehi A
AU - Kheiry H
AU - Kiani FK
AU - Ahmadi A
AU - Masjedi A
AU - Ghani S
AU - Rafiee B
AU - Karpisheh V
AU - Hajizadeh F
AU - Atyabi F
AU - Assali A
AU - Tekie FSM
AU - Namdar A
AU - Ghalamfarsa G
AU - Sojoodi M
AU - Jadidiniaragh F
TI - Retraction Note: Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression (Pharm Res, (2020), 37, (196), 10.1007/S11095-020-02892-Y)
JO - Pharmaceutical Research
VL - 39
IS - 12
SP - 3383
EP - 3384
PY - 2022
ER -

Science Communicator Platform

Authors

Abstract